Wide Ranks

ATOS

Atossa Therapeutics, Inc.

1.28

Top Statistics
Market Cap 161 M Forward PE -5.12 Revenue Growth 0.00 %
Current Ratio 13.30 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.93 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 74 M Total Cash Per Share 0.5940 Total Debt
Total Debt To Equity Current Ratio 13.30 Book Value Per Share 0.5860
All Measures
Short Ratio 2027.00 % Message Board Id finmb_100256926 Fax 206 902 9658
Shares Short Prior Month 13 M Return On Equity -0.3130 City Seattle
Uuid 35c3fa09-af5c-3e0c-b0a7-3be2f00c1ed7 Previous Close 1.29 First Trade Date Epoch Utc 1 B
Book Value 0.5860 Beta 1.23 Volume 429524
Price To Book 2.18 Last Split Date 1 B Fifty Two Week Low 0.7000
Total Cash Per Share 0.5940 Shares Short Previous Month Date 1 B Target Median Price 6.50
Audit Risk 7 Max Age 86400 Sand P52 Week Change 0.3133
Target Mean Price 5.83 Net Income To Common -26911000 Short Percent Of Float 0.0990
Implied Shares Outstanding 125 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 922670 Average Volume10days 922670 Total Cash 74 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0006 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 1.29 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.41 Open 1.27 Free Cashflow -12761625
State WA Dividend Yield 0.00 % Return On Assets -0.2035
Time Zone Short Name EST Board Risk 8 Trailing Eps -0.2100
Day Low 1.24 Address1 107 Spring Street Shares Outstanding 125 M
Compensation Risk 9 Price Hint 4 Target High Price 7.00
Website https://www.atossatherapeutics.com 52 Week Change 0.7297 Average Volume 604968
Forward Eps -0.2700 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 1290.00 % Last Split Factor 1:12 Regular Market Day High 1.32
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 2.31
Day High 1.32 Shares Short 12 M Regular Market Open 1.27
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0990 Operating Cashflow -19550000 Currency USD
Time Zone Full Name America/New_York Market Cap 161 M Is_nasdaq_100 False
Zip 98104 Quote Type EQUITY Industry Biotechnology
Long Name Atossa Therapeutics, Inc. Overall Risk 8 Regular Market Day Low 1.24
Held Percent Institutions 0.2821 Current Price 1.28 Enterprise To Ebitda -2.93
Financial Currency USD Current Ratio 13.30 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 117 M
Two Hundred Day Average 1.38 Governance Epoch Date 1 B Enterprise Value 86 M
Forward PE -5.12 Regular Market Volume 429524 Ebitda -29462000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

It also develops immunotherapy/chimeric antigen receptor therapy programs.

The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.

Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.